Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-257 in Rheumatoid Arthritis
NCT02531178Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alicapistat in rheumatoid arthritis (RA) (3 cohorts), sponsored by AbbVie Inc. Primary endpoints: Proportion of subjects with adverse events, Change in Vital signs and 4 more. Started Jul 2015; status: completed.
02
Drugs
alicapistat
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02531178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531178.